Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome.

Nature communications - 20 Dec 2021

Storm Catherine S, Kia Demis A, Almramhi Mona M, Bandres-Ciga Sara, Finan Chris, Hingorani Aroon D, Wood Nicholas W

Abstract excerpt

Parkinson's disease is a neurodegenerative movement disorder that currently has no disease-modifying treatment, partly owing to inefficiencies in drug target identification and validation. We use Mendelian randomization to investigate over 3,000 genes that encode druggable proteins and predict their efficacy as drug targets for Parkinson's disease. We use expression and protein quantitative trait loci to mimic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Gene Expression Regulation

Share to Genome, Human

Share to Mendelian Randomization Analysis

Share to Parkinson Disease

Share to Quantitative Trait Loci

Source

Open in PubMed Open full text

Identifiers

PMID: 34930919
DOI: 10.1038/s41467-021-26280-1
PMCID: PMC8688480

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome.PMID 34930919Read ↗

Finding drug targeting mechanisms with genetic evidence for Parkinson’s diseaseSemantic proximity Read ↗

Genetics and Treatment Response in Parkinson’s Disease: An Update on Pharmacogenetic StudiesSemantic proximity Read ↗

Evaluating Lipid-Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization.Semantic proximity Read ↗

Drug Repurposing for Parkinson’s Disease: A Large-Scale Multi-Cohort StudySemantic proximity Read ↗

Brain Proteome-Wide and Transcriptome-Wide Asso-ciation Studies, Bayesian Colocalization, and Mendelian Randomization Analyses Reveal Causal Genes of Parkinson's Disease.Semantic proximity Read ↗

TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitroSemantic proximity Read ↗

Mendelian Randomization Study Using Dopaminergic Neuron-Specific eQTL Nominates Potential Causal Genes for Parkinson's Disease.Semantic proximity Read ↗

The Parkinson's Disease Mendelian Randomization Research Portal.Semantic proximity Read ↗

From GWAS to clinical utility in Parkinson's disease.Semantic proximity Read ↗

Modeling Parkinson's Disease Heterogeneity to Accelerate Precision Medicine.Semantic proximity Read ↗

A network-based systems genetics framework identifies pathobiology and drug repurposing in Parkinson’s diseaseSemantic proximity Read ↗

Identifying the genetic links between Parkinson’s disease and non-motor symptoms: novel insights into disease mechanismsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.